This article is a part of Startup Spotlight, a series that features young, up-and-coming startups.

Photo credit: Qualia Therapeutics
Transcranial magnetic stimulation requires patients to attend clinics for up to seven weeks. Yet clinicians often lack data on how a patient’s brain actually changes during this treatment.
This information gap led to the creation of Qualia Therapeutics. The software platform tracks brain responses throughout the entire stimulation process.
😟 Problem
Clinicians deliver magnetic pulses to stimulate brain areas for conditions like chronic pain and depression. They track outward symptoms but lack reliable measurements of actual brain activity over time.
Patients can wait up to seven weeks before knowing if the treatment affected their brain. Meanwhile, clinics keep expensive machines booked for long courses that may not be working.
💡 Solution
Qualia Therapeutics developed a software system that works alongside existing magnetic stimulation equipment. The platform records and analyzes electroencephalography data before and after each treatment session.
The clinical reporting software relies on several core mechanisms, including:
- Integrates brain recordings, stimulation settings, and patient outcomes into a single clinical report.
- Evaluates data quality and tracks specific measures of brain activity over time.
- Benchmarks quantum optimization methods against classical models to help personalize future treatment protocols.

Image credit: Qualia Therapeutics
📊 Market size
The global market for transcranial magnetic stimulation devices is projected to reach US$1.5 billion in 2026. This sector is currently growing at nearly 10% annually.
The startup estimates each clinic represents about US$210,000 in lifetime value. Targeting 100 to 300 clinics in Europe presents an annual revenue opportunity
🤝 Team
- Nerses Khachatryan. Founder and CEO. He directs product development using his background in biotech and pharmaceutical innovation.
- Diana Khachatryan. Co-founder and CSO. She manages scientific research and the regulatory pathway toward European CE marking.
- Bella Harutyunyan. Co-founder and CBDO. She handles commercial strategy following her previous work with the World Bank and UNICEF.




